Compositions comprising genome segments and methods of using the same

• US 7,217,699 B2
• Filed: 01/03/2001
• Issued: 05/15/2007
• Est. Priority Date: 01/03/2000
• Status: Expired due to Fees

• Current Assignee: Panagenic International, Inc.
• Original Assignee: Panagenic International, Inc.
• Inventors: Yakubov, Leonid A.
• Primary Examiner(s): PRIEBE, SCOTT DAVID
• Application Number:
  US09/753,892
• Publication Number:
  US 20020025522A1
• Time in Patent Office: 2,323 Days
• Field of Search: 514/44, 435/455
• US Class Current: 514/44.00R
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 48/005 characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered

Abstract

Methods of treating an individual who has a disease or disorder associated with one or more genetic mutations or undesirable alleles in genomic DNA of the individual, or preventing an individual from developing a disease or disorder associated with one or more genetic mutations or undesirable alleles in genomic DNA of the individual, by replacing a segment of genomic DNA that has a mutated sequence or undesirable allele with a corresponding segment of DNA that has a non-mutated sequence or desirable allele, are disclosed. Methods of inducing tolerance and preventing transplant rejection in a recipient, methods of inducing tolerance and or reducing allergies are disclosed and method of increasing fertility in a woman are disclosed. Each of the methods comprises replacing a segment of genomic DNA in an individual with a corresponding segment of DNA from another. An apparatus for doing large scale PCR preparations is disclosed. Pharmaceutical compositions that comprise a plurality of polynucleotide molecules which collectively comprise an essentially complete genome in polynucleotide molecules having about 100–3000 nucleotides are disclosed.

Claims

1. A method of treating a human individual who has a disease or disorder associated with exposure to ionizing radiation comprising the step of

administering to the individual who has been exposed to ionizing radiation a therapeutically effective amount of a plurality of polynucleotide molecules that are free of vector sequences, wherein

the plurality of polynucleotide molecules collectively comprises an essentially complete human genome derived from autologous DNA collected from the individual before the individual is exposed to the ionizing radiation;

and each of the plurality of polynucleotide molecules having about 100–

3000 nucleotides.

2. The method of claim 1 wherein the plurality of polynucleotide molecules are free DNA.

3. The method of claim 1 wherein at least 80% of polynucleotide molecules administered are about 200–

3000 nucleotides in length.

4. The method of claim 1 wherein at least 80% of polynucleotide molecules administered are about 200–

3000 nucleotides in length and have an average length of about 300–

1000.

5. The method of claim 1 wherein at least 80% of polynucleotide molecules administered are about 300–

2000 nucleotides in length.

6. The method of claim 1 wherein the plurality of polynucleotide molecules are administered in an amount of 0.4–

20 g of polynucleotides having 200–

3000 nucleotides each.

7. The method of claim 1 wherein the plurality of polynucleotide molecules are administered in an amount of 1–

16 g of polynucleotides having 200–

3000 nucleotides each.

8. The method of claim 1 wherein the plurality of polynucleotide molecules are administered by a regiment selected from the group consisting of:

continuous infusion, multiple doses administered hourly, multiple doses administered daily, multiple doses administered every other day, multiple doses administered weekly.